# Fulgent Genetics, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Fulgent Genetics, Inc.). ## Overview Fulgent Genetics, Inc. is a technology-based healthcare company with two businesses: laboratory services and therapeutic development. Its core operations provide genetic testing, anatomic pathology, and related laboratory interpretation services, while its therapeutic arm is developing cancer drug candidates using a nanoencapsulation and targeted therapy platform. ## Products & services • Molecular genetic testing and precision diagnostics • Comprehensive anatomic pathology services • Digital pathology with AI-enabled slide digitization • BioPharma services and licensing revenue • Therapeutic development for cancer drug candidates - **Laboratory testing services** (85%) — Genetic, molecular, and anatomic pathology testing sold on a per-test basis to physicians, institutions, and payors. - **Digital pathology and AI-enabled workflows** (5%) — Digitized pathology slide review and related technology that supports faster, scalable interpretation. - **BioPharma services** (5%) — Technology licensing, CRO-related services, and other revenue tied to pharmaceutical and biotech customers. - **Therapeutic development** (5%) — Early-stage oncology drug development using a nanoencapsulation and targeted therapy platform. - Molecular genetic testing and precision diagnostics - Comprehensive anatomic pathology services - Digital pathology with AI-enabled slide digitization - BioPharma services and licensing revenue - Therapeutic development for cancer drug candidates ## Customers Fulgent sells primarily to insurance payors, institutional customers, and individual payors, with laboratory tests purchased on a test-by-test basis rather than under long-term contracts. A small number of customers can represent a large share of revenue, and the company has disclosed significant concentration in one large laboratory customer. Its therapeutic development and BioPharma activities also serve pharmaceutical, biotechnology, and CRO counterparties. - **Insurance payors** (primary) — Reimburse genetic and pathology tests; pricing and claims processing drive realized revenue. - **Institutional laboratory customers** (primary) — Buy outsourced testing capacity and specialized assays when internal capabilities are limited. - **Physicians and ordering providers** (secondary) — Order tests for patient diagnosis and treatment decisions, especially precision diagnostics. - **Pharmaceutical and biotechnology companies** (secondary) — Buy licensing, CRO-related, and other BioPharma services tied to therapeutic development. - **Individual payors** (secondary) — Direct consumers or self-pay patients using the company’s testing menu for specific clinical needs. - Insurance payors that reimburse diagnostic testing - Hospitals and institutional labs buying outsourced testing - Physicians ordering pathology and genetic tests - Individual payors seeking direct diagnostic services - Pharma, biotech, and CRO customers for BioPharma services ## Geography Fulgent is headquartered in the United States and operates CLIA-licensed laboratories in the U.S., which are central to its testing and pathology business. The company also generates non-U.S. revenue, with management citing China, Australia, and Canada as meaningful international markets, and it noted that Puerto Rico and the U.S. Virgin Islands are now grouped with U.S. geographic revenue. International exposure matters because reimbursement, currency, and trade-policy conditions can affect both demand and margins. - **United States** (79%) — Estimated from management disclosure that non-U.S. revenue was 21% in 2025. - **Non-U.S.** (21%) — Management disclosed 2025 non-U.S. revenue of $26.1 million, or 21% of total revenue. - United States is the main operating base and lab footprint - CLIA-licensed laboratories support domestic testing services - Non-U.S. revenue includes China, Australia, and Canada - Puerto Rico and U.S. Virgin Islands are now counted in U.S. revenue - International sales add currency and reimbursement exposure ## Strategy Fulgent is trying to use its scalable testing platform, broad menu, and centralized lab operations to improve margins and win share in precision diagnostics. At the same time, it is building a second growth engine in therapeutic development, aiming to evolve from a diagnostics company into a broader precision medicine platform. - **Broaden the laboratory customer base** (short-term) — Revenue concentration in one large customer creates volatility and can quickly pressure growth. - **Improve lab efficiency and gross margin** (medium-term) — Centralized operations and scalable workflows support better unit economics in a price-competitive market. - **Build therapeutic development into a second platform** (long-term) — The company wants to diversify beyond diagnostics and create long-term value in oncology. - Expand the testing menu while keeping pricing affordable - Use AI and digital pathology to improve workflow efficiency - Scale and centralize lab operations to support margins - Reduce customer concentration by broadening the base - Develop oncology assets through nanoencapsulation and targeted therapy ## Risks Fulgent faces customer concentration risk, reimbursement pressure, and regulatory exposure because its testing revenue depends on payor decisions and a limited number of large accounts. It also operates in a heavily regulated laboratory environment with supply-chain dependence on key vendors such as Illumina, while its therapeutic pipeline adds clinical, FDA, and impairment risk typical of early-stage drug development. - **Customer concentration** [high] — A single large laboratory customer has represented about 22-23% of revenue and may reduce orders. - **Reimbursement and payor risk** [high] — Revenue depends on insurance reimbursement rates, claims processing, and payor audits. - **Regulatory and licensing compliance** [high] — Testing operations require ongoing compliance with federal, state, local, and foreign lab rules. - **Supplier concentration** [medium] — The company relies on a limited number of suppliers for reagents and sequencing equipment. - **Therapeutic development failure** [high] — Early-stage oncology assets may not prove safe, effective, or commercially viable. - **Cybersecurity and data privacy** [medium] — Security incidents could expose sensitive patient data and create liability and reputational damage. - Revenue concentration in one large customer can swing results sharply - Reimbursement and claims processing can delay or reduce collections - Laboratory licensing and compliance failures could disrupt operations - Key suppliers like Illumina create equipment and reagent dependency - Therapeutic candidates may fail in development or face FDA delays ## Accounting Revenue is recognized when a report is delivered to the ordering physician or customer, net of contractual and other adjustments, so reimbursement estimates directly affect reported sales. Investors should also watch customer credit-loss provisions, goodwill and intangible impairment, and the accounting for acquired IPR&D and licensing arrangements in the therapeutic business, all of which can materially change earnings and asset values. - **Revenue recognition and variable consideration** — Can change reported revenue and bad-debt expense - **Credit loss allowance** — Affects SG&A and net income - **Goodwill and intangible impairment** — Can create large non-cash write-downs - **Acquired IPR&D valuation** — Can materially affect balance sheet and future impairment risk - **Gross-margin sharing and licensing revenue timing** — Creates quarter-to-quarter volatility - Revenue is recognized on delivery of the test report, net of adjustments - Estimated collections from payors drive reported revenue and receivables - Credit-loss provisions can move with customer and payor collectability - Goodwill and intangible assets are tested for impairment annually - Acquired IPR&D and licensing values depend on uncertain development outcomes --- *Last updated: 2026-04-28T20:09:13.492491+00:00*